PRSS2 and COVID-19: Narsoplimab, a high-affinity fully human immunoglobulin gamma 4 (IgG4), has been reported to block the lectin pathway by binding to mannan-binding lectin-associated serine protease-2 (MASP-2), which binds to COVID-19 N protein in disease progression.